PTC Therapeutics | PTCT - Assets


PTC Therapeutics reported $2.64B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Alnylam Pharmaceuticals USD 4.85B 285.64M Sep/2025
Amgen USD 90.14B 2.24B Sep/2025
Biogen USD 29.21B 877.3M Sep/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Cytokinetics USD 1.44B 210.92M Sep/2025
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Gilead Sciences USD 58.53B 2.81B Sep/2025
Incyte USD 6.33B 509M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Ironwood Pharmaceuticals USD 396.06M 53.12M Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
PTC Therapeutics USD 2.64B 9.54M Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
TG Therapeutics USD 1.03B 322.41M Sep/2025
Ultragenyx Pharmaceutical USD 1.19B 115.82M Sep/2025
Vertex Pharmaceuticals USD 24.86B 825.6M Sep/2025
Xencor USD 868.81M 10.61M Sep/2025